<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0408222408
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VASCODIPINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vascodipine contains the active substance Amlodipine which belongs to a group of medicines called calcium antagonists.</p><p>Vascodipine is used to treat high blood pressure (hypertension) or a certain type of chest pain called angina, a rare form of which is Prinzmetal&#39;s or variant angina.</p><p>In patients with high blood pressure your medicine works by relaxing blood vessels, so that blood passes through them more easily. In patients with angina Vascodipine works by improving blood supply to the heart muscle which then receives more oxygen and as a result chest pain is prevented. Your medicine does not provide immediate relief of chest pain from angina.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vascodipine</strong></p><ul><li>If you are allergic (hypersensitive) to Vascodipine, or any of the other ingredients of your medicine listed in section 6, or to any other calcium antagonists. This may be itching, reddening of the skin or difficulty in breathing.</li><li>If you have severe low blood pressure (hypotension)</li><li>If you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body)</li><li>If you suffer from heart failure after a heart attack</li></ul><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Vascodipine.</p><p>You should inform your doctor if you have or have had any of the following conditions:</p><ul><li>Recent heart attack</li><li>Heart failure</li><li>Severe increase in blood pressure (Hypertensive crisis)</li><li>Liver disease</li><li>You are elderly and your dose needs to be increased</li></ul><p><strong>Children and adolescents</strong></p><p>Vascodipine has not been studied in children under the age of 6 years. Vascodipine should only be used for hypertension in children and adolescents from 6 years to 17 years of age (see section 3).</p><p>For more information, talk to your doctor.</p><p><strong>Other medicines and Vascodipine</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines,</p><p>including medicines obtained without a prescription.</p><p>Vascodipine may affect or be affected by other medicines, such as:</p><ul><li>ketoconazole, itraconazole (anti-fungal medicines)</li><li>ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV)</li><li>rifampicin, erythromycin, clarithromycin (antibiotics)</li><li>hypericum perforatum (St. John&rsquo;s Wort)</li><li>verapamil, diltiazem (heart medicines)</li><li>dantrolene (infusion for severe body temperature abnormalities)</li><li>tacrolimus, sirolimus, temsirolimus, and everolimus (medicines used to alter the way your immune system works)</li><li>simvastatin (cholesterol lowering medicine)</li><li>cyclosporine (an immunosuppressant)</li></ul><p>Vascodipine may lower your blood pressure even more if you are already taking other medicines to treat your high blood pressure.</p><p><strong>Vascodipine with food and drink</strong></p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking Vascodipine. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Vascodipine.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><u>Pregnancy</u></p><p>The safety of amlodipine in human pregnancy has not been established. If you think you might be pregnant, or are planning to get pregnant, you must tell your doctor before you take Vascodipine.</p><p><u>Breast-feeding</u></p><p>Amlodipine has been shown to pass into breast milk in small amounts. If you are breast-feeding or about to start breast-feeding you must tell your doctor before taking Vascodipine.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Vascodipine may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your</p><p>doctor or pharmacist if you are not sure.</p><p>The recommended initial dose is Vascodipine 5 mg once daily. The dose can be increased to Vascodipine 10 mg once daily.</p><p>This medicine can be used before or after food and drinks. You should take this medicine at the same time each day with a drink of water. Do not take Vascodipine with grapefruit juice.</p><p dir="RTL"><strong>Use in children and adolescents</strong></p><p>For children and adolescents (6-17 years old), the recommended usual starting dose is 2.5 mg a day. The maximum recommended dose is 5 mg a day.</p><p>It is important to keep taking the tablets. Do not wait until your tablets are finished before seeing your doctor.</p><p><strong>If you take more Vascodipine than you should</strong></p><p>Taking too many tablets may cause your blood pressure to become low or even dangerously low. You may feel dizzy, lightheaded, faint or weak. If blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness. Seek immediate medical attention if you take too many Vascodipine tablets.</p><p><strong>If you forget to take Vascodipine</strong></p><p>Do not worry. If you forget to take a tablet, leave out that dose completely. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Vascodipine</strong></p><p>Your doctor will advise you how long to take this medicine. Your condition may return if you</p><p>stop using this medicine before you are advised.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, VASCODIPINE tablets can cause side effects although not everybody gets them.</p><p>Visit your doctor <strong>immediately </strong>if you experience any of the following side effects after taking this medicine.</p><ul><li>Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing</li><li>Swelling of eyelids, face or lips</li><li>Swelling of the tongue and throat which causes great difficulty breathing</li><li>Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, toxic epidermal necrolysis) or other allergic reactions</li><li>Heart attack, abnormal heartbeat</li><li>Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell</li></ul><p>The following <strong>very common side effect </strong>has been reported. If this causes you problems or if it</p><p><strong>lasts for more than one week</strong>, you should <strong>contact your doctor.</strong></p><p><strong>Very common: may affect more than 1 in 10 people</strong></p><ul><li>Oedema (fluid retention)</li></ul><p>The following <strong>common side effects </strong>have been reported. If any of these cause you problems or if they <strong>last for more than one week</strong>, you should <strong>contact your doctor.</strong></p><p><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li>Headache, dizziness, sleepiness (especially at the beginning of treatment)</li><li>Palpitations (awareness of your heartbeat), flushing</li><li>Abdominal pain, feeling sick (nausea)</li><li>Altered bowel habits, diarrhoea, constipation, indigestion</li><li>Tiredness, weakness</li><li>Visual disturbances, double vision</li><li>Muscle cramps</li><li>Ankle swelling</li></ul><p>Other side effects that have been reported include the following list. If any of these get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><ul><li>Mood changes, anxiety, depression, sleeplessness</li><li>Trembling, taste abnormalities, fainting</li><li>Numbness or tingling sensation in your limbs, loss of pain sensation</li><li>Ringing in the ears</li><li>Low blood pressure</li><li>Sneezing/running nose caused by inflammation of the lining of the nose (rhinitis)</li><li>Cough</li><li>Dry mouth, vomiting (being sick)</li><li>Hair loss, increased sweating, itchy skin, red patches on skin, skin discolouration</li><li>Disorder in passing urine, increased need to urinate at night, increased number of times of passing urine</li><li>Inability to obtain an erection, discomfort or enlargement of the breasts in men</li><li>Pain, feeling unwell</li><li>Joint or muscle pain, back pain</li><li>Weight increase or decrease</li></ul><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p><strong>Very rare: may affect up to 1 in 10,000 people</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased numbers of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excess sugar in blood (hyperglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A disorder of the nerves which can cause muscular weakness, tingling or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal bloating (gastritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased muscle tension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of blood vessels, often with skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorders combining rigidity, tremor, and/or movement disorders</p><p><strong>Not known frequency cannot be estimated from the available data</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trembling, rigid posture, mask-like face, slow movements and a shuffling, unbalanced walk</p><p><strong>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original pack to protect from light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Vascodipine after the expiry date which is stated on the carton after Exp. The expiry date refers to the last day of the month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Amlodipine as Amlodipine Besilate (BP) equivalent to 2.5, 5 or 10 mg</p><p>Amlodipine.</p><p>Other ingredients are Microcrystalline cellulose PH 102, Calcium hydrogen phosphate, Sodium starch glycolate, Magnesium stearate, Colloid anhydrous silica.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                VASCODIPINE 2.5 mg tablets: white to off white, circular tablets with bevelled edges having break on one side and “RP 46” on the other side.
VASCODIPINE 5 mg tablets: white to off white, circular tablets with bevelled edges having “RP 21” on one side and plain on the other side.
VASCODIPINE 10 mg tablets: white to off white, circular tablets with bevelled edges having “RP 22” on one side and plain on the other side.

Pack size:  
VASCODIPINE 2.5 ,5 ,10 mg tablets: Transparent PVC-PVDC film / Aluminum foil blister pack of 10 tablets.
Each pack contains 3 blisters.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O. Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing authorisation holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in (10/2020)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فاسكودبين يحتوي على المادة الفعالة أملوديبين التي تنتمي إلى مجموعة من الأدوية تسمى مثبطات الكالسيوم.</p><p dir="RTL">يستخدم فاسكودبين لعلاج ارتفاع ضغط الدم (ضغط الدم المرتفع) أو نوع معين من آلام الصدر يسمى الذبحة الصدرية، وشكل نادر منه وهو برنزميتال أو الذبحة الصدرية المتغيرة.</p><p dir="RTL">في المرضى الذين يعانون من ارتفاع ضغط الدم يعمل الدواء عن طريق ارخاء الاوعيه الدمويه، بحيث يمر الدم من خلالها بسهولة أكبر. في المرضى الذين يعانون من الذبحة الصدرية يعمل فاسكودبين من خلال تحسين تدفق الدم الى عضلة القلب التي تستقبل بدورها المزيد من الأكسجين و نتيجة لذلك يتم منع ألم الصدر.هذا الدواء لا يوفر التحسن الفوري من آلام الصدر الناتجة عن الذبحة الصدرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فاسكودبين</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من حساسية (فرط الحساسية) من فاسكودبين، أو أي من المكونات الأخرى في هذا الدواء المدرجة في القسم 6، أو أي من مثبطات الكالسيوم الأخرى. قد تكون على صورة حكة واحمرار في الجلد أو صعوبة في التنفس.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك انخفاض شديد في ضغط الدم (انخفاض الضغط)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك تضيق في صمام القلب الأورطي (تضيق الأبهر) أو صدمة قلبية (حالة حيث يصبح قلبك غير قادر على توفير ما يكفي من الدم إلى الجسم)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من قصور في القلب بعد اصابته بأزمة قلبية</p><p dir="RTL"><strong>التحذيرات و الاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول فاسكودبين.</p><p dir="RTL">يجب إبلاغ الطبيب إذا لديك أو كان لديك أي من الحالات التالية:</p><ul><li dir="RTL">نوبة قلبية مؤخرا</li><li dir="RTL">قصور القلب</li><li dir="RTL">زيادة حادة في ضغط الدم (أزمة ارتفاع ضغط الدم)</li><li dir="RTL">أمراض الكبد</li><li dir="RTL">كنت مسن وتحتاج إلى زيادة الجرعة</li></ul><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم يتم دراسة تأثير فاسكودبين عند الأطفال دون سن 6 سنوات. يجب استخدام فاسكودبين فقط لعلاج ارتفاع ضغط الدم لدى الأطفال والمراهقين من عمر 6 سنوات إلى 17 سنة (انظر القسم 3).</p><p dir="RTL">لمزيد من المعلومات ، تحدث إلى طبيبك.</p><p dir="RTL"><strong>الأدوية </strong><strong>ال</strong><strong>أخرى و فاسكودبين</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">فاسكودبين قد يؤثر على أو يتأثر بالأدوية الأخرى، مثل:</p><ul><li dir="RTL">الكيتوكونازول، الايتراكونازول (الأدوية المضادة للفطريات)</li><li dir="RTL">ريتونافير، اندينافير، نلفينافير (ما يسمى مثبطات الأنزيم البروتيني المستخدمة لعلاج فيروس نقص المناعة البشرية)</li><li dir="RTL">ريفامبيسين، اريثروميسين، كلاريثروميسين (المضادات الحيوية)</li><li dir="RTL">هايبريكم بيرفوراتوم (نبتة سانت جون)</li><li dir="RTL">فيراباميل، ديلتيازيم (أدوية القلب)</li><li dir="RTL">دانترولين (محلول للاعتلال الشديد في درجة حرارة الجسم)</li><li dir="RTL">تاكروليموس وسيروليموس وتيمسيروليموس وإيفيروليموس (الأدوية المستخدمة لتغيير الطريقة التي يعمل بها جهاز المناعة)</li><li dir="RTL">سيمفاستاتين (دواء لخفض الكوليسترول)</li><li dir="RTL">السيكلوسبورين (مثبط للمناعة)</li></ul><p dir="RTL">فاسكودبين قد يخفض ضغط دمك أكثر إذا كنت تتناول بالفعل أدوية أخرى لعلاج ارتفاع ضغط الدم.</p><p dir="RTL"><strong>فاسكودبين مع الطعام والشراب </strong></p><p dir="RTL">يجب عدم تناول عصير الجريب فروت و فاكهة الجريب فروت من قبل الناس الذين يتناولون فاسكودبين.</p><p dir="RTL">ذلك لأن الجريب فروت وعصير الجريب فروت يمكن أن يتسببا في زيادة في مستويات المادة الفعالة أملوديبين في الدم ، الذي يمكن أن يسبب زيادة غير متوقعة في تأثير فاسكودبين لخفض ضغط الدم .</p><p dir="RTL"><strong>الحمل و الرضاعة الطبيعية</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">مأمونية أملوديبين أثناء الحمل في البشر لم يتم التأكد منها. إذا كنتِ تعتقدين أنكِ قد تكوني حاملا أو تخططين للحمل، يجب إخبار الطبيب قبل تناول فاسكودبين.</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">يتم إفراز أملوديبين في حليب الثدي بكميات صغيرة. إذا كنتِ ترضعين طفلك الرضاعة الطبيعية أو على وشك أن تبدأي الرضاعة الطبيعية يجب أن تخبري طبيبك قبل تناول فاسكودبين.</p><p dir="RTL">إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">فاسكودبين قد يؤثر على قدرتك على القيادة أو استخدام الآلات. إذا كانت الأقراص تجعلك تشعر بالغثيان، بالدوار أو التعب، أو تتسبب في الصداع، لا تقم بالقيادة أو استخدام الآلات واتصل بطبيبك على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائما هذا الدواء تماما كما قال لك طبيبك. يجب عليك التحقق من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الجرعة الأولية المعتادة هي فاسكودبين 5 ملجم مرة واحدة يوميا. يمكن زيادة الجرعة إلى 10 ملجم فاسكودبين مرة واحدة يوميا.</p><p dir="RTL">الدواء يمكن استخدامه قبل أو بعد الطعام والشراب. يجب تناول الدواء في نفس الوقت كل يوم مع شربة ماء. لا تتناول فاسكودبين مع عصير الجريب فروت.</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">للأطفال والمراهقين (6-17 سنة) فإن الجرعة المبدئية المعتادة الموصى بها هي 2.5 ملجم يوميا. الجرعة القصوى الموصى بها هي 5 ملجم يوميا.</p><p dir="RTL">من المهم الحفاظ على تناول الأقراص. لا تنتظر حتى انتهاء الأقراص قبل رؤية الطبيب.</p><p dir="RTL"><strong>إذا تناولت فاسكودبين أكثر مما يجب </strong></p><p dir="RTL">تناول الكثير من الأقراص قد يتسبب في انخفاض ضغط الدم أو حتى يجعله منخفض بشكل خطير. قد تشعر بالدوار، دوخة، الاغماء أو الضعف. انخفاض ضغط الدم بشكل خطير يمكن أن يسبب صدمة. جلدك قد يشعر ببرودة ورطوبة ويمكن أن تفقد وعيك.</p><p dir="RTL">يجب الحصول على الرعاية الطبية الفورية إذا تناولت الكثير من أقراص فاسكودبين</p><p dir="RTL"><strong>إذا نسيت تناول فاسكودبين</strong></p><p dir="RTL">لا تقلق. إذا نسيت تناول قرص ، تجاهل تلك الجرعة تماما. تناول الجرعة التالية في الوقت المحدد. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>إذا توقفت عن تناول فاسكودبين</strong></p><p dir="RTL">طبيبك سوف ينصحك بمدة تناول الدواء. قد تعود حالتك إذا توقفت عن استخدام الدواء قبل أن ينصح الطبيب بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن تتسبب أقراص فاسكودبين في آثار جانبية ، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">قم بزيارة الطبيب <strong>فوراً</strong> إذا واجهتك أي من الآثار الجانبية التالية بعد تناول هذا الدواء.</p><ul><li dir="RTL">أزيز مفاجئ، ألم في الصدر، ضيق في التنفس أو صعوبة في التنفس.</li><li dir="RTL">تورم الجفون والوجه أو الشفتين.</li><li dir="RTL">تورم في اللسان والحلق مما يسبب صعوبة كبيرة في التنفس. &nbsp;</li><li dir="RTL">تفاعلات جلدية شديدة بما في ذلك الطفح الجلدي الشديد، شرى (ارتيكاريا)، احمرار الجلد على جسمك كله، والحكة الشديدة، التقرحات، تقشر الجلد وتورم في الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون) أو أمراض الحساسية الأخرى.</li><li dir="RTL">النوبات القلبية، ضربات القلب غير طبيعية</li><li dir="RTL">التهاب البنكرياس الذي قد يسبب آلام بالبطن وآلام الظهر مصحوبا بتوعك شديد</li></ul><p dir="RTL">تم الإبلاغ عن <strong>الآثار الجانبية</strong> <strong>الشائعة جداً</strong> التالية. إذا كانت تسبب لك مشاكل أو إذا كانت <strong>تستمر لأكثر من أسبوع واحد</strong>، <strong>يجب عليك الاتصال بطبيبك.</strong></p><p dir="RTL"><strong>شائعة جداً</strong>: قد تؤثر على أكثر من 1 من كل 10 أشخاص</p><ul><li dir="RTL">الوذمة (احتباس السوائل)</li></ul><p dir="RTL">تم الإبلاغ عن <strong>الآثار الجانبية</strong> <strong>الشائعة</strong> التالية. إذا كانت تسبب لك مشاكل أو إذا كانت <strong>تستمر لأكثر من أسبوع واحد</strong>، <strong>يجب عليك الاتصال بطبيبك.</strong></p><p dir="RTL"><strong>شائعة</strong>: قد تؤثر على حتى 1 من كل 10 أشخاص</p><ul><li dir="RTL">صداع ، دوار ، نعاس (خاصة في بداية العلاج)</li><li dir="RTL">الخفقان (الوعي بضربات قلبك) ، احمرار</li><li dir="RTL">ألم في البطن ، الشعور بالغثيان</li><li dir="RTL">عادات الأمعاء المتغيرة ، الإسهال ، الإمساك ، عسر الهضم</li><li dir="RTL">التعب والضعف</li><li dir="RTL">اضطرابات بصرية وازدواج الرؤية</li><li dir="RTL">تشنجات العضلات</li><li dir="RTL">تورم الكاحل</li></ul><p dir="RTL">آثار جانبية أخرى تم الإبلاغ عنها في القائمة التالية. إذا كان أي من هذه خطيرة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي</p><p dir="RTL"><strong>غير شائعة</strong>: قد تؤثر على حتى 1 من كل 100 شخص</p><ul><li dir="RTL">تغيرات في المزاج، والقلق، والاكتئاب، والأرق</li><li dir="RTL">ارتعاش، احساس غير طبيعي بالطعم، والاغماء</li><li dir="RTL">التنميل أو الإحساس بالوخز في أطرافك ؛ فقدان الإحساس بالألم</li><li dir="RTL">طنين في الأذنين</li><li dir="RTL">انخفاض ضغط الدم</li><li dir="RTL">العطس / سيلان الأنف الناجم عن التهاب بطانة الأنف (التهاب مخاطية الأنف)</li><li dir="RTL">سعال</li><li dir="RTL">جفاف الفم والقيء (المرض)</li><li dir="RTL">فقدان الشعر، وزيادة التعرق، وحكة في الجلد، والبقع الحمراء على الجلد، تغير لون الجلد</li><li dir="RTL">اضطرابات في التبول، وزيادة الحاجة إلى التبول في الليل، زيادة عدد مرات التبول</li><li dir="RTL">عدم القدرة على الحصول على الانتصاب. عدم الراحة أو تضخم الثديين عند الرجال</li><li dir="RTL">الألم، والشعور بالإعياء</li><li dir="RTL">آلام المفاصل أو العضلات، ، وآلام الظهر</li><li dir="RTL">زيادة الوزن أو نقصانه</li></ul><p dir="RTL"><strong>نادرة</strong>: قد تؤثر على حتى 1 من كل 1000 شخص</p><ul><li dir="RTL">ارتباك</li></ul><p dir="RTL"><strong>نادرة جدا:</strong> قد تؤثر على حتى 1 من كل 10000 شخص</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء، وانخفاض في الصفائح الدموية التي قد تؤدي إلى كدمات غير معتادة أو سهولة النزف</p><ul><li dir="RTL">السكر الزائد في الدم (ارتفاع سكر الدم)</li><li dir="RTL">اضطراب في الأعصاب الذي يمكن أن يسبب ضعف عضلي ، وخز أو تخدر</li><li dir="RTL">تورم اللثة</li><li dir="RTL">انتفاخ البطن (التهاب المعدة)</li><li dir="RTL">اضطرابات في وظائف الكبد، والتهاب في الكبد (الالتهاب الكبدي)، اصفرار الجلد (اليرقان)، زيادة انزيم الكبد التي قد يكون لها تأثير على بعض الفحوصات الطبية</li><li dir="RTL">زيادة توتر العضلات</li><li dir="RTL">التهاب الأوعية الدموية، وغالبا مع طفح جلدي</li><li dir="RTL">الحساسية للضوء</li><li dir="RTL">اضطرابات تجمع بين تصلب، ورعشة، و / ​​أو اضطرابات حركية</li></ul><p dir="RTL"><strong>تكرارها غير معروف لا يمكن تقدير التكرار من البيانات المتاحة</strong></p><ul dir="rtl"><li>&nbsp;ارتجاف ، ووضعية صلبة ، ووجه يشبه القناع ، وحركات بطيئة ، ومشى غير متوازن</li></ul><p dir="RTL"><strong>إذا أصبح أي من الآثار الجانبية خطير أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي و نظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول أقراص فاسكودبين بعد تاريخ انتهاء الصلاحية المذكور على الشريط أو العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أملوديبين على هيئة أملوديبين بيسيلات (BP) ما يعادل 2.5 أو 5 أو 10 ملجم أملوديبين.</p><p dir="RTL">المكونات الأخرى هي ميكروكريستالين السليلوز PH 102 ، فوسفات هيدروجين الكالسيوم ، جلايكولات نشا الصوديوم ، ستيرات المغنيسيوم ، السيليكا الغروية اللامائية.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص</strong><strong> </strong><strong>فاسكودبين 2,5ملجم</strong>: أقراص مستديرة بيضاء إلى بيضاء داكنة ذات حواف مشطوفة مع خط للكسر من جانب و &quot;RP 46&quot; من الجانب الآخر.</p><p dir="RTL"><strong>أقراص</strong><strong> </strong><strong>فاسكودبين 5ملجم</strong>: أقراص مستديرة بيضاء إلى بيضاء داكنة ذات حواف مشطوفة &quot;RP 21&quot; على جانب واحد و منبسطة على الجانب الآخر.</p><p dir="RTL"><strong>أقراص</strong><strong> </strong><strong>فاسكودبين 10ملجم </strong>: أقراص مستديرة بيضاء إلى بيضاء داكنة ذات حواف مشطوفة &quot;RP 22&quot; على جانب واحد و منبسطة على الجانب الآخر.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ (10/2020)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vascodipine 2.5 mg tablets
Vascodipine 5 mg tablets
Vascodipine 10 mg tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Ingredient: amlodipine.
One tablet contains amlodipine besilate equivalent to 2.5 mg amlodipine.
One tablet contains amlodipine besilate equivalent to 5 mg amlodipine.
One tablet contains amlodipine besilate equivalent to 10 mg amlodipine.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vascodipine 2.5 mg Tablets: white to off-white circular tablet with bevelled edges having break on one side and “RP 46” on the other side.

Vascodipine 5 mg Tablets: white to off-white circular tablet with bevelled edges having “RP 21” on one side and plain on the other side.

Vascodipine 10 mg Tablets: white to off-white circular tablet with bevelled edges having “RP 22” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Hypertension</p><p>- Chronic stable</p><p>- Vasospastic (Prinzmetal&#39;s) angina</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><strong><em>Adults</em></strong></p><p>For both hypertension and angina the usual initial dose is 5 mg Amlodipine once daily which may be increased to a maximum dose of 10 mg depending on the individual patient&#39;s response.</p><p>In hypertensive patients, Amlodipine has been used in combination with a thiazide diuretic, alpha blocker, beta blocker, or an angiotensin converting enzyme inhibitor. For angina, Amlodipine may be used as monotherapy or in combination with other antianginal medicinal products in patients with angina that is refractory to nitrates and/or to adequate doses of beta blockers.</p><p>No dose adjustment of Amlodipine is required upon concomitant administration of thiazide diuretics, beta blockers, and angiotensin-converting enzyme inhibitors.</p><p><u>Special populations</u></p><p><strong><em>Elderly patients</em></strong></p><p>Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care (see sections 4.4 and 5.2).</p><p><strong><em>Patients with hepatic impairment</em></strong></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p><strong><em>Patients with renal impairment</em></strong></p><p>Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dialysable.</p><p><strong><em>Paediatric population</em></strong></p><p>Children and adolescents with hypertension from 6 years to 17 years of age.</p><p>The recommended antihypertensive oral dose in paediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in paediatric patients (see sections 5.1 and 5.2).</p><p><strong><em>Children under 6 years old</em></strong></p><p>No data are available.</p><p><u>Method of administration</u></p><p>Tablet for oral administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlodipine is contraindicated in patients with:
•	hypersensitivity to dihydropyridine derivatives, amlodipine or to any of the excipients listed in section 6.1.
•	severe hypotension.
•	shock (including cardiogenic shock).
•	obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis).
•	haemodynamically unstable heart failure after acute myocardial infarction.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p><u>Patients with cardiac failure</u></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p><u>Patients with hepatic impairment</u></p><p>The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p><u>Elderly patients</u></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p><u>Patients with renal impairment</u></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on amlodipine</u></p><p><em>CYP3A4 inhibitors</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure resulting in an increased risk of hypotension. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>&nbsp;</p><p><em>CYP3A4 inducers</em></p><p>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p>&nbsp;</p><p><em>Dantrolene (infusion)</em></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><u>&nbsp;</u></p><p><u>Effects of amlodipine on other medicinal products</u></p><p>The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p>&nbsp;</p><p><em>Tacrolimus</em></p><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine but the pharmacokinetic mechanism of this interaction is not fully understood. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p><em>&nbsp;</em></p><p><em>Mechanistic Target of Rapamycin (mTOR) Inhibitors</em></p><p>mTOR inhibitors such as sirolimus, temsirolimus, and everolimus are CYP3A substrates. Amlodipine is a weak CYP3A inhibitor. With concomitant use of mTOR inhibitors, amlodipine may increase exposure of mTOR inhibitors.</p><p>&nbsp;</p><p><em>Cyclosporine</em></p><p>No drug interaction studies have been conducted with cyclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of cyclosporine were observed. Consideration should be given for monitoring cyclosporine levels in renal transplant patients on amlodipine, and cyclosporine dose reductions should be made as necessary.</p><p>&nbsp;</p><p><em>Simvastatin</em></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin or warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p>Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3-7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been observed and reported during treatment with amlodipine with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukocytopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Depression, mood changes (including anxiety), insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Confusion</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Somnolence, dizziness, headache (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tremor, dysgeusia, syncope, hypoaesthesia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hypertonia, peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>Extrapyramidal disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Visual disturbance (including diplopia)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Myocardial infarction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough, rhinitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain, nausea, dyspepsia, altered bowel habits (including diarrhoea and constipation)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vomiting, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice, hepatic enzyme increased*</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, rash, exanthema, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ankle swelling, muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia, back pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Micturition disorder, nocturia, increased urinary frequency</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Impotence, gynaecomastia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue, asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Chest pain, pain, malaise</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight increased, weight decreased</p></td></tr></tbody></table><p>*mostly consistent with cholestasis</p><p>Exceptional cases of extrapyramidal syndrome have been reported.</p><p>&nbsp;</p><p><strong>To report any side effects:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Center (NPC):</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In humans experience with intentional overdose is limited.</p><p><u>Symptoms</u></p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p><u>Treatment</u></p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Calcium channel blockers, selective calcium channel blockers with mainly vascular effects. ATC Code: C08CA01.</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>1) Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>2) The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery</p><p>in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p>&nbsp;</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>&nbsp;</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1 mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>&nbsp;</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><u>&nbsp;</u></p><p><u>Use in patients with coronary artery disease (CAD)</u></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-centre, randomized, double-blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 1. Incidence of significant clinical outcomes for CAMELOT</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><u>Cardiovascular event rates,</u></p><p><u>No. (%)</u></p></td><td colspan="2" style="vertical-align:top"><p><u>Amlopidine vs. Placebo</u></p></td></tr><tr><td style="vertical-align:top"><p>Outcomes</p></td><td style="vertical-align:top"><p>Amlopidine</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Enalapril</p></td><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td style="vertical-align:top"><p><em>P</em>&nbsp;Value</p></td></tr><tr><td style="vertical-align:top"><p><u>Primary Endpoint</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Adverse cardiovascular events</p></td><td style="vertical-align:top"><p>110 (16.6)</p></td><td style="vertical-align:top"><p>151 (23.1)</p></td><td style="vertical-align:top"><p>136 (20.2)</p></td><td style="vertical-align:top"><p>0.69 (0.54-0.88)</p></td><td style="vertical-align:top"><p>.003</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><u>Individual Components</u></p></td></tr><tr><td style="vertical-align:top"><p>Coronary revascularization</p></td><td style="vertical-align:top"><p>78 (11.8)</p></td><td style="vertical-align:top"><p>103 (15.7)</p></td><td style="vertical-align:top"><p>95 (14.1)</p></td><td style="vertical-align:top"><p>0.73 (0.54-0.98)</p></td><td style="vertical-align:top"><p>.03</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for angina</p></td><td style="vertical-align:top"><p>51 (7.7)</p></td><td style="vertical-align:top"><p>84 (12.8)</p></td><td style="vertical-align:top"><p>86 (12.8)</p></td><td style="vertical-align:top"><p>0.58 (0.41-0.82)</p></td><td style="vertical-align:top"><p>.002</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>14 (2.1)</p></td><td style="vertical-align:top"><p>19 (2.9)</p></td><td style="vertical-align:top"><p>11 (1.6)</p></td><td style="vertical-align:top"><p>0.73 (0.37-1.46)</p></td><td style="vertical-align:top"><p>.37</p></td></tr><tr><td style="vertical-align:top"><p>Stroke or TIA</p></td><td style="vertical-align:top"><p>6 (0.9)</p></td><td style="vertical-align:top"><p>12 (1.8)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>0.50 (0.19-1.32)</p></td><td style="vertical-align:top"><p>.15</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>5 (0.7)</p></td><td style="vertical-align:top"><p>2.46 (0.48-12.7)</p></td><td style="vertical-align:top"><p>.27</p></td></tr><tr><td style="vertical-align:top"><p>Hospitalization for CHF</p></td><td style="vertical-align:top"><p>3 (0.5)</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>0.59 (0.14-2.47)</p></td><td style="vertical-align:top"><p>.46</p></td></tr><tr><td style="vertical-align:top"><p>Resuscitated cardiac arrest</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>.04</p></td></tr><tr><td style="vertical-align:top"><p>New-onset peripheral vascular disease</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>2.6 (0.50-13.4)</p></td><td style="vertical-align:top"><p>.24</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p></td></tr></tbody></table><p><u>Use in patients with heart failur</u><u>e</u></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that Amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>&nbsp;</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that Amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>&nbsp;</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of Amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, Amlodipine had no effect on total cardiovascular mortality. In this same population Amlodipine was associated with increased reports of pulmonary oedema.</p><p>&nbsp;</p><p><u>Treatment to prevent heart attack trial (ALLHAT)</u></p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>&nbsp;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>&nbsp;</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p>&nbsp;</p><p><u>Use in children (aged 6 years and older)</u></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5 mg dose, and 5.0 mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>&nbsp;</p><p>The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood has also not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption, distribution, plasma protein binding:</u>&nbsp;After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg.&nbsp;<em>In vitro&nbsp;</em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><u>Biotransformation/elimination</u></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><em>Hepatic impairment</em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p><em>Elderly population</em></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p><em>Paediatric population</em></p><p>A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Reproductive toxicology</u></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><u>Impairment of fertility</u></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m<sup>2</sup>&nbsp;basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><u>Carcinogenesis, mutagenesis</u></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m<sup>2</sup>&nbsp;basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose PH 102</p><p>Calcium hydrogen phosphate</p><p>Sodium starch glycollate</p><p>Magnesium stearate</p><p>Colloid anhydrous silica</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p><p>Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transparent PVC-PVDC/Aluminum foil blister pack of 10 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:0px"><tbody><tr><td><p>Keep medicines out of reach and sight of children</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorization holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>